ENvue Medical Statistics
Total Valuation
ENvue Medical has a market cap or net worth of $1.11 million. The enterprise value is -$1.92 million.
Important Dates
The last earnings date was Monday, May 18, 2026, after market close.
| Earnings Date | May 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
ENvue Medical has 1.10 million shares outstanding. The number of shares has increased by 2,229.20% in one year.
| Current Share Class | 1.10M |
| Shares Outstanding | 1.10M |
| Shares Change (YoY) | +2,229.20% |
| Shares Change (QoQ) | +28.29% |
| Owned by Insiders (%) | 21.81% |
| Owned by Institutions (%) | 6.71% |
| Float | 860,377 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.44 |
| Forward PS | n/a |
| PB Ratio | 0.03 |
| P/TBV Ratio | 31.75 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.09, with a Debt / Equity ratio of 0.04.
| Current Ratio | 1.09 |
| Quick Ratio | 0.72 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -106.58% and return on invested capital (ROIC) is -41.39%.
| Return on Equity (ROE) | -106.58% |
| Return on Assets (ROA) | -32.78% |
| Return on Invested Capital (ROIC) | -41.39% |
| Return on Capital Employed (ROCE) | -34.05% |
| Weighted Average Cost of Capital (WACC) | 6.25% |
| Revenue Per Employee | $182,357 |
| Profits Per Employee | -$1.20M |
| Employee Count | 14 |
| Asset Turnover | 0.11 |
| Inventory Turnover | 1.06 |
Taxes
| Income Tax | -307,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -91.79% in the last 52 weeks. The beta is 1.59, so ENvue Medical's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | -91.79% |
| 50-Day Moving Average | 1.59 |
| 200-Day Moving Average | 3.78 |
| Relative Strength Index (RSI) | 31.95 |
| Average Volume (20 Days) | 653,795 |
Short Selling Information
The latest short interest is 10,982, so 1.00% of the outstanding shares have been sold short.
| Short Interest | 10,982 |
| Short Previous Month | 16,233 |
| Short % of Shares Out | 1.00% |
| Short % of Float | 1.28% |
| Short Ratio (days to cover) | 0.04 |
Income Statement
In the last 12 months, ENvue Medical had revenue of $2.55 million and -$16.78 million in losses. Loss per share was -$26.69.
| Revenue | 2.55M |
| Gross Profit | 153,000 |
| Operating Income | -11.74M |
| Pretax Income | -18.49M |
| Net Income | -16.78M |
| EBITDA | -10.84M |
| EBIT | -11.74M |
| Loss Per Share | -$26.69 |
Full Income StatementBalance Sheet
The company has $4.22 million in cash and $1.20 million in debt, with a net cash position of $3.03 million or $2.75 per share.
| Cash & Cash Equivalents | 4.22M |
| Total Debt | 1.20M |
| Net Cash | 3.03M |
| Net Cash Per Share | $2.75 |
| Equity (Book Value) | 33.50M |
| Book Value Per Share | 30.44 |
| Working Capital | 611,000 |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$9.37 million and capital expenditures -$60,000, giving a free cash flow of -$9.43 million.
| Operating Cash Flow | -9.37M |
| Capital Expenditures | -60,000 |
| Depreciation & Amortization | 897,000 |
| Net Borrowing | -1.42M |
| Free Cash Flow | -9.43M |
| FCF Per Share | -$8.57 |
Full Cash Flow StatementMargins
| Gross Margin | 5.99% |
| Operating Margin | -459.66% |
| Pretax Margin | -724.32% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ENvue Medical does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2,229.20% |
| Shareholder Yield | n/a |
| Earnings Yield | -1,509.33% |
| FCF Yield | -848.65% |
Analyst Forecast
| Price Target | $22,000.00 |
| Price Target Difference | 2,178,117.82% |
| Analyst Consensus | n/a |
| Analyst Count | 0 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on August 12, 2025. It was a reverse split with a ratio of 1:10.
| Last Split Date | Aug 12, 2025 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
ENvue Medical has an Altman Z-Score of -3.65 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.65 |
| Piotroski F-Score | 1 |
